Picard Medical Showcases Next-Gen Artificial Heart Tech at ACC.26
Event summary
- Picard Medical, parent company of SynCardia, will present preclinical data on its ‘Emperor’ next-generation total artificial heart at the American College of Cardiology (ACC) Annual Scientific Session on March 29, 2026.
- The ‘Emperor’ aims to combine fully implantable architecture with physiologic autoregulation, building on the SynCardia Total Artificial Heart’s existing performance.
- SynCardia has performed over 2,100 implants of its Total Artificial Heart across 27 countries.
- Engineering Project Manager Duffy Elmer will present the poster at 11:00 a.m. – 12:00 p.m. on Sunday, March 29, 2026.
The big picture
Picard Medical's focus on the ‘Emperor’ represents a strategic bet on expanding the total artificial heart market beyond the current bridge-to-transplant application. The move towards a fully implantable system addresses a key limitation of the existing SynCardia device, potentially opening up opportunities for long-term support and improved patient quality of life. However, the company faces significant regulatory and clinical hurdles in bringing this next-generation technology to market, and the success of the program will be critical for Picard Medical’s long-term growth prospects.
What we're watching
- Regulatory Pathway
- The success of the ‘Emperor’ hinges on navigating FDA and Health Canada approval processes, potentially requiring extensive clinical trials to demonstrate safety and efficacy compared to the existing SynCardia Total Artificial Heart.
- Clinical Adoption
- Widespread adoption of the ‘Emperor’ will depend on clinician acceptance and integration into existing heart failure treatment protocols, which may be slow given the established use of the current SynCardia device.
- Competitive Landscape
- The emergence of competing fully implantable artificial heart technologies could erode SynCardia’s market share and necessitate further innovation to maintain a competitive edge.
Related topics